“Talk HIV, test HIV”: ECDC welcomes first European HIV testing week
Outbreak of hepatitis A continues – ECDC/EFSA update assessment
Europe’s response to HIV: ECDC reports identify key areas for action
Reversing the HIV epidemic: Europe needs to scale-up prevention, testing and treatment
In a two-day conference organised in collaboration between the Maltese Presidency of the Council of the European Union Conference and ECDC , HIV experts from across the European Union discussed how to reverse the HIV epidemic and how to prepare Europe to achieve the set target of ending AIDS by 2030.
The continuum of HIV care: how is Europe doing?
The continuum of HIV care is a framework that enables countries to monitor the effectiveness of their HIV response - from diagnosis towards viral suppression (which means that the virus is no longer detectable in the blood). This report provides a snapshot of the status of the continuum of care for the whole region as well as each of the 48 countries reporting at least some continuum data.
Epidemiological update: Hepatitis A outbreaks in the EU/EEA mostly affecting men who have sex with men
Since the last ECDC rapid risk assessment, which was published on 24 February 2017, 10 EU Member States (Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Portugal, Sweden and the United Kingdom (Public Health England and Health Protection Scotland) reported 387 new confirmed cases of hepatitis A, with one of the strains matching the three clusters currently circulating in the EU.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
Pre-exposure prophylaxis in the EU/EEA setting: challenges and opportunities
Although clinical trials and other studies have demonstrated the efficacy and effectiveness of pre-exposure prophylaxis (PrEP) for HIV and existing guidelines have recommended making PrEP available within combination HIV prevention packages, there is not yet clear consensus in Europe with regard to whether and how to implement PrEP.